Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus

被引:51
作者
Albrecht, Joerg
Werth, Victoria P.
机构
[1] Univ Penn, Dept Dermatol, Philadelphia, PA 19119 USA
[2] John H Stroger Jr Hosp Cook Cty, Dept Med, Div Dermatol, Chicago, IL USA
[3] Philadelphia VA Med Ctr, Philadelphia VA Dermatol, Philadelphia, PA USA
关键词
cutaneous lupus erythematosus; patient outcome assessment; reproducibility of results; validity;
D O I
10.1111/j.1529-8019.2007.00117.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Skin involvement is a frequent presenting manifestation of systemic lupus erythematosus (SLE). Cutaneous lupus erythematosus (CLE), frequently occurring without SLE, may be even more common than SLE. Until recently, clinical instruments to measure skin involvement in CLE did not exist, hampering clinical research in this field. In this paper the present authors describe outcome instruments for SLE and outline the considerations underlying the design and validation of an outcome instrument for CLE, the cutaneous lupus disease area and severity index. These studies serve as a model for development and validation of standardized instruments that can be applied to other cutaneous diseases, particularly autoimmune diseases, in order to facilitate epidemiologic studies and clinical trials.
引用
收藏
页码:93 / 101
页数:9
相关论文
共 32 条
[1]   The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus [J].
Albrecht, J ;
Taylor, L ;
Berlin, JA ;
Dulay, S ;
Ang, G ;
Fakharzadeh, S ;
Kantor, J ;
Kim, E ;
Militello, G ;
McGinnis, K ;
Richardson, S ;
Treat, J ;
Vittorio, C ;
Van Voorhees, A ;
Werth, VP .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (05) :889-894
[2]  
Albrecht J, 2006, HANDB SYST AUTOIMMUN, V5, P207, DOI 10.1016/S1571-5078(05)05015-4
[3]  
ARINGER M, 2006, Z RHEUMATOL
[4]   EVENING PRIMROSE OIL AND ATOPIC ECZEMA [J].
BERTHJONES, J ;
THOMPSON, J ;
GRAHAMBROWN, RAC .
LANCET, 1995, 345 (8948) :520-520
[5]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[6]  
Bonilla-Martinez ZL, 2006, ARTHRITIS RHEUM, V54, pS434
[7]   Measuring quality of life - Are quality of life measures patient centred? [J].
Carr, AJ ;
Higginson, IJ .
BRITISH MEDICAL JOURNAL, 2001, 322 (7298) :1357-1360
[8]  
*CDER, 2005, SYST LUP ER DEV DRUG
[9]   Outcome measures of disease severity in atopic eczema [J].
Charman, C ;
Williams, H .
ARCHIVES OF DERMATOLOGY, 2000, 136 (06) :763-769
[10]  
Charman CR, 1999, BRIT J DERMATOL, V140, P109